DPx buys its way into U.S. biologics with Gallus acquisition

DPx, the result of a $2.6 billion merger of Patheon and DSM Pharmaceutical Products, has acquired U.S. contract manufacturer Gallus BioPharmaceuticals. In exchange for an undisclosed sum, the conglomerate gets two biologics facilities in the U.S. and about 400 new employees to run them. More